JP7012078B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP7012078B2
JP7012078B2 JP2019520504A JP2019520504A JP7012078B2 JP 7012078 B2 JP7012078 B2 JP 7012078B2 JP 2019520504 A JP2019520504 A JP 2019520504A JP 2019520504 A JP2019520504 A JP 2019520504A JP 7012078 B2 JP7012078 B2 JP 7012078B2
Authority
JP
Japan
Prior art keywords
heterocyclyl
carbocyclyl
mmol
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519616A5 (enExample
JP2019519616A (ja
Inventor
マッカーティー クリーブ
デビッド ハルグレイブ ジョナサン
アレクサンダー ヘイ ダンカン
ボーレガード スコフィールド トーマス
ウェント ナオミ
Original Assignee
エンタープライズ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンタープライズ セラピューティクス リミテッド filed Critical エンタープライズ セラピューティクス リミテッド
Publication of JP2019519616A publication Critical patent/JP2019519616A/ja
Publication of JP2019519616A5 publication Critical patent/JP2019519616A5/ja
Application granted granted Critical
Publication of JP7012078B2 publication Critical patent/JP7012078B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019520504A 2016-06-21 2017-06-21 化合物 Active JP7012078B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1610854.0A GB201610854D0 (en) 2016-06-21 2016-06-21 Compounds
GB1610854.0 2016-06-21
PCT/GB2017/051815 WO2017221008A1 (en) 2016-06-21 2017-06-21 Compounds

Publications (3)

Publication Number Publication Date
JP2019519616A JP2019519616A (ja) 2019-07-11
JP2019519616A5 JP2019519616A5 (enExample) 2020-08-06
JP7012078B2 true JP7012078B2 (ja) 2022-02-10

Family

ID=56895059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520504A Active JP7012078B2 (ja) 2016-06-21 2017-06-21 化合物

Country Status (5)

Country Link
US (1) US10759785B2 (enExample)
EP (1) EP3472154B1 (enExample)
JP (1) JP7012078B2 (enExample)
GB (1) GB201610854D0 (enExample)
WO (1) WO2017221008A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
KR20220050126A (ko) 2019-06-12 2022-04-22 티엠이엠16에이 리미티드 호흡기 질환을 치료하기 위한 화합물
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
EP4052760B1 (en) 2019-10-31 2024-03-13 FUJIFILM Corporation Pyrazine derivative or salt thereof, and use of same
EP4190402B1 (en) 2020-07-30 2025-08-27 FUJIFILM Corporation Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof
TW202237090A (zh) 2020-12-11 2022-10-01 英商Ｔｍｅｍ16Ａ有限公司 治療呼吸道疾病之化合物
EP4281075A2 (en) * 2021-01-25 2023-11-29 Pharmi Norden AB Method of treating a skin disorder by administering an amiloride derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502827A (ja) 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
WO2015007516A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel 5-substituted benzimidazolium compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
EP1670474A4 (en) 2003-08-18 2008-08-06 Parion Sciences Inc CYCLIC PYRAZINOYLGUANIDINE AS SODIUM CHANNEL BLOCKER
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2484308A1 (en) 2006-07-24 2012-08-08 International Stem Cell Corporation Synthetic cornea from retinal stem cells
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
WO2009139948A1 (en) 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
MX2010012441A (es) 2008-05-13 2010-12-06 Novartis Ag Derivados de acido 3,5-diamino-6-cloro-pirazin-2-carboxilico y su uso como bloqueadores del canal de sodio epitelial para el tratamiento de enfermedades de las vias respiratorias.
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
NO2773633T3 (enExample) 2011-11-02 2017-12-30
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
WO2013181232A2 (en) 2012-05-29 2013-12-05 Michael Ross Johnson Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
WO2014044849A1 (en) 2012-09-24 2014-03-27 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
WO2015003958A1 (en) 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
WO2015007519A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel benzimidazolium compounds
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
EP3030555B1 (en) 2013-08-08 2019-01-30 Boehringer Ingelheim International GmbH Novel pyrazine amide compounds
US10155749B2 (en) 2015-01-12 2018-12-18 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
EP3298022B1 (en) * 2015-08-20 2019-06-05 Boehringer Ingelheim International GmbH Novel annelated phenoxyacetamides
MX2018002006A (es) * 2015-08-20 2018-06-19 Boehringer Ingelheim Int Benzamidas apareadas novedosas.
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502827A (ja) 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
WO2015007516A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel 5-substituted benzimidazolium compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Membrane Biol，1987年，Vol.95，p.171-185

Also Published As

Publication number Publication date
US20190233402A1 (en) 2019-08-01
US10759785B2 (en) 2020-09-01
WO2017221008A1 (en) 2017-12-28
EP3472154B1 (en) 2020-08-12
JP2019519616A (ja) 2019-07-11
GB201610854D0 (en) 2016-08-03
EP3472154A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
JP2019519616A (ja) 化合物
CN113365988B (zh) Shp2抑制剂及其应用
KR102827138B1 (ko) 화합물
JP6419990B2 (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
CN107108606B (zh) 用于治疗和预防乙型肝炎病毒感染的新的6,7-二氢苯并[a]喹嗪-2-酮衍生物
JP6980014B2 (ja) ＥＮａＣ阻害剤としてのベンゾジアゾリウム化合物
TWI641592B (zh) 激酶抑制劑
WO2021104431A1 (zh) Kras g12c抑制剂化合物及其用途
JP7333793B2 (ja) 化合物
CN112771027A (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CN114981243A (zh) 用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
KR20230042129A (ko) 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
CN112020496A (zh) 作为rho激酶抑制剂的苯并吡唑类化合物
JP2022521453A (ja) 複素環式の誘導体
CN103476765A (zh) 抑制错构瘤肿瘤细胞的方法
CN103097367A (zh) 苯丙酸化合物、其制备方法及其医药用途
CN116693447B (zh) 酮酰胺类衍生物及其制药用途
KR20250023339A (ko) 페닐 트라이아졸 mll1-wdr5 단백질-단백질 상호작용 저해제
JP7269923B2 (ja) 呼吸器疾患治療のためのＥＮａＣ阻害剤としてのビス（ペンタヒドロキシヘキシル）アミノ置換された２－｛［（３－アミノ－ピラジン－２－イル）ホルムアミド］メチル｝－１Ｈ－１，３－ベンゾジアゾール－３－イウム誘導体
HK1201821A1 (zh) 活化ampk的吲哚類和吲唑類化合物
CN115551846A (zh) 1,4,5,6-四氢嘧啶-2-胺衍生物
CN112979675A (zh) 一种小分子含硫杂环化合物
CN106103423B (zh) 吡嗪类化合物
CN107207477A (zh) 用于治疗病毒性疾病的亚氨基糖
WO2025051161A1 (zh) 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220117

R150 Certificate of patent or registration of utility model

Ref document number: 7012078

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250